Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update. Issue 9 (2nd September 2019)

• Record Type: Journal Article
• Authors: Costagliola, Ciro; Morescalchi, Francesco; Duse, Sarah; Romano, Davide; Mazza, Giuseppina; Parmeggiani, Francesco; Bartollino, Silvia; Semeraro, Francesco
• Is Part Of: Expert opinion on drug safety. Volume 18:Issue 9(2019)
• Page Start: 803
• Page End: 815
• Publication Date: 2019-09-02
• Subjects: Abicipar -- aflibercept -- age-related macular degeneration -- anti-VEGF -- bevacizumab -- conbercept -- ranibizumab -- thromboembolic adverse events; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2019.1643838
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction : Intravitreal anti-VEGF is the most effective therapy for wet AMD, although systemic effects on the endothelium cannot be excluded. Areas covered : The purpose of this review was to evaluate risk of thromboembolic events associated with intravitreal anti-VEGF. Expert opinion : Current data are insufficient to confirm the safety of these compounds, due to the paucity of specific studies. Thus, pharmacovigilance for all anti-VEGF should be improved to verify the true role of anti-VEGF in the occurrence of systemic adverse events.